I somewhat share Baldwidx concerns that we may have a potential issue with NNZ-2591 development, being that we do not have complete control over what indications can be developed for NNZ-2591 on our own.From the NEU announcement 14/7/2023;
Neuren has an obligation not to develop NNZ-2591 or any other product for North America in an indication for which Acadia develops trofinetide, except for Phelan-McDermid, Pitt Hopkins, Angelman and Prader-Willi syndromes.
If Acadia decide to begin to developing trofinetide across an expansive range of syndromes how will that affect NNZ-2591's value?
I can't answer whether or not they can they do that, or whether they would they do that, or even if Acadia could afford to, however it certainly bares considering.
- Forums
- ASX - By Stock
- ANAVEX MEETS ENDPOINTS PHASE2 RETT
I somewhat share Baldwidx concerns that we may have a potential...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.99 |
Change
0.540(2.64%) |
Mkt cap ! $2.682B |
Open | High | Low | Value | Volume |
$20.56 | $21.55 | $20.54 | $12.48M | 591.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 435 | $20.97 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.99 | 1001 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1455 | 20.910 |
1 | 1010 | 20.900 |
4 | 3490 | 20.880 |
2 | 1455 | 20.870 |
1 | 2540 | 20.840 |
Price($) | Vol. | No. |
---|---|---|
20.990 | 1001 | 2 |
21.090 | 1040 | 2 |
21.110 | 1455 | 1 |
21.150 | 1455 | 1 |
21.190 | 1455 | 1 |
Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |